1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue 1.4 Market by Type 1.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Oral Medications 1.4.3 Temozolomide 1.4.4 Radiosensitizers 1.4.5 Nitrosoureas Drugs 1.4.6 Radiation Therapy 1.4.7 Chemotherapy 1.5 Market by Application 1.5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2020 VS 2026 1.5.2 Hospitals 1.5.3 Clinics 1.5.4 Ambulatory Surgical Centers 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends 2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Perspective (2015-2026) 2.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Regions 2.2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Recurrent Glioblastoma Multiforme (GBM) Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Market Size 3.1.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue (2015-2020) 3.1.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio 3.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2019 3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served 3.4 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service 3.5 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026) 4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Type (2015-2020) 4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026) 5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) 5.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020) 6.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in North America (2019-2020) 6.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) 6.4 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) 7 Europe 7.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020) 7.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Europe (2019-2020) 7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) 7.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) 8 China 8.1 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020) 8.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in China (2019-2020) 8.3 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) 8.4 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) 9 Japan 9.1 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020) 9.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Japan (2019-2020) 9.3 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) 9.4 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020) 10.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) 10.4 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) 11 India 11.1 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020) 11.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in India (2019-2020) 11.3 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) 11.4 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2015-2020) 12.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Central & South America (2019-2020) 12.3 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) 12.4 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Astrazeneca 13.1.1 Astrazeneca Company Details 13.1.2 Astrazeneca Business Overview 13.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 13.1.4 Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020)) 13.1.5 Astrazeneca Recent Development 13.2 Roche 13.2.1 Roche Company Details 13.2.2 Roche Business Overview 13.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 13.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) 13.2.5 Roche Recent Development 13.3 GlaxoSmithKline 13.3.1 GlaxoSmithKline Company Details 13.3.2 GlaxoSmithKline Business Overview 13.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 13.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) 13.3.5 GlaxoSmithKline Recent Development 13.4 Merck 13.4.1 Merck Company Details 13.4.2 Merck Business Overview 13.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 13.4.4 Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) 13.4.5 Merck Recent Development 13.5 Pfizer 13.5.1 Pfizer Company Details 13.5.2 Pfizer Business Overview 13.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 13.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) 13.5.5 Pfizer Recent Development 13.6 AngioChem 13.6.1 AngioChem Company Details 13.6.2 AngioChem Business Overview 13.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 13.6.4 AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) 13.6.5 AngioChem Recent Development 13.7 Vascular Biogeneics 13.7.1 Vascular Biogeneics Company Details 13.7.2 Vascular Biogeneics Business Overview 13.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 13.7.4 Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) 13.7.5 Vascular Biogeneics Recent Development 14 Analyst's Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Recurrent Glioblastoma Multiforme (GBM) Treatment Key Market Segments Table 2. Key Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Table 3. Ranking of Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Oral Medications Table 6. Key Players of Temozolomide Table 7. Key Players of Radiosensitizers Table 8. Key Players of Nitrosoureas Drugs Table 9. Key Players of Radiation Therapy Table 10. Key Players of Chemotherapy Table 11. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 12. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (US$ Million): 2020 VS 2026 Table 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (2015-2020) (US$ Million) Table 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2015-2020) Table 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 16. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2021-2026) Table 17. Market Top Trends Table 18. Key Drivers: Impact Analysis Table 19. Key Challenges Table 20. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Growth Strategy Table 21. Main Points Interviewed from Key Recurrent Glioblastoma Multiforme (GBM) Treatment Players Table 22. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Players (2015-2020) (Million US$) Table 23. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players (2015-2020) Table 24. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2019) Table 25. Global Recurrent Glioblastoma Multiforme (GBM) Treatment by Players Market Concentration Ratio (CR5 and HHI) Table 26. Key Players Headquarters and Area Served Table 27. Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service Table 28. Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market Table 29. Mergers & Acquisitions, Expansion Plans Table 30. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$) Table 31. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Type (2015-2020) Table 32. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2021-2026) Table 33. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Application (2015-2020) Table 34. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$) Table 35. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Application (2021-2026) Table 36. North America Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$) Table 37. North America Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020) Table 38. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$) Table 39. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020) Table 40. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$) Table 41. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020) Table 42. Europe Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$) Table 43. Europe Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020) Table 44. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$) Table 45. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020) Table 46. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$) Table 47. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020) Table 48. China Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$) Table 49. China Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020) Table 50. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$) Table 51. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020) Table 52. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$) Table 53. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020) Table 54. Japan Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$) Table 55. Japan Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020) Table 56. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$) Table 57. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020) Table 58. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$) Table 59. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020) Table 60. Southeast Asia Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$) Table 61. Southeast Asia Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020) Table 62. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$) Table 63. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020) Table 64. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$) Table 65. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020) Table 66. India Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$) Table 67. India Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020) Table 68. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$) Table 69. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020) Table 70. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$) Table 71. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020) Table 72. Central & South America Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (2019-2020) (Million US$) Table 73. Central & South America Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share (2019-2020) Table 74. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2015-2020) (Million US$) Table 75. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2015-2020) Table 76. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2015-2020) (Million US$) Table 77. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2015-2020) Table 78. Astrazeneca Company Details Table 79. Astrazeneca Business Overview Table 80. Astrazeneca Product Table 81. Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$) Table 82. Astrazeneca Recent Development Table 83. Roche Company Details Table 84. Roche Business Overview Table 85. Roche Product Table 86. Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$) Table 87. Roche Recent Development Table 88. GlaxoSmithKline Company Details Table 89. GlaxoSmithKline Business Overview Table 90. GlaxoSmithKline Product Table 91. GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$) Table 92. GlaxoSmithKline Recent Development Table 93. Merck Company Details Table 94. Merck Business Overview Table 95. Merck Product Table 96. Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$) Table 97. Merck Recent Development Table 98. Pfizer Company Details Table 99. Pfizer Business Overview Table 100. Pfizer Product Table 101. Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$) Table 102. Pfizer Recent Development Table 103. AngioChem Company Details Table 104. AngioChem Business Overview Table 105. AngioChem Product Table 106. AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$) Table 107. AngioChem Recent Development Table 108. Vascular Biogeneics Company Details Table 109. Vascular Biogeneics Business Overview Table 110. Vascular Biogeneics Product Table 111. Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2015-2020) (Million US$) Table 112. Vascular Biogeneics Recent Development Table 113. Research Programs/Design for This Report Table 114. Key Data Information from Secondary Sources Table 115. Key Data Information from Primary Sources List of Figures Figure 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type: 2020 VS 2026 Figure 2. Oral Medications Features Figure 3. Temozolomide Features Figure 4. Radiosensitizers Features Figure 5. Nitrosoureas Drugs Features Figure 6. Radiation Therapy Features Figure 7. Chemotherapy Features Figure 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2020 VS 2026 Figure 9. Hospitals Case Studies Figure 10. Clinics Case Studies Figure 11. Ambulatory Surgical Centers Case Studies Figure 12. Recurrent Glioblastoma Multiforme (GBM) Treatment Report Years Considered Figure 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth 2015-2026 (US$ Million) Figure 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions: 2020 VS 2026 Figure 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2021-2026) Figure 16. Porter's Five Forces Analysis Figure 17. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players in 2019 Figure 18. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2019 Figure 19. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2019 Figure 20. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 22. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 23. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 25. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 26. Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 27. Bottom-up and Top-down Approaches for This Report Figure 28. Data Triangulation Figure 29. Key Executives Interviewed

Astrazeneca Roche GlaxoSmithKline Merck Pfizer AngioChem Vascular Biogeneics